Intismeran Proves Effective as Personalised mRNA Skin Cancer Vaccine

Gist Pharmaceutical companies Moderna and Merck have successfully developed intismeran, a pioneering personalised mRNA cancer vaccine. When administered alongside an existing immunotherapy drug, the vaccine significantly reduces the risk of death and recurrence in patients with melanoma skin cancer . While this marks a major breakthrough in precision oncology and mRNA applications, its immediate relevance to India is constrained by the extreme rarity of melanoma in the country and the prohibitive costs of such advanced immunotherapies. Background Traditional cancer treatments generally rely on a generic approach chemotherapy, radiation that targets all rapidly dividing cells, often causing severe collateral damage to healthy tissues. Messenger RNA mRNA is a single-stranded molecule that acts as a courier, carrying genetic instructions from a cell's DNA in the nucleus to the cellular machinery that manufactures proteins. Neoantigens are mutated proteins that exist exclusively on the surface of cancerous cells, acting as unique biological identifiers for a tumor. Because cancer mutations differ completely from person to person, a universal cancer vaccine is ineffective; treatments must be personalised to recognize the specific neoantigens of an individual patient.…